GO
Loading...

Pharmaceuticals

More

  • FDA Turns Over Dendreon Documents Wednesday, 5 Mar 2008 | 3:49 PM ET

    When I got back from the Pfizer analyst meeting in New York City this afternoon, I found a treasure trove of PDF documents in one of my inboxes from a couple of Dendreon/Provenge proponents from their Freedom of Information Act request to the Food and Drug Administration...

  • Pfizer CEO: We're Ready For Generic Lipitor Wednesday, 5 Mar 2008 | 2:25 PM ET

    I'm in the press room at the midtown Manhattan hotel where Pfizer is holding its analyst meeting. There's just over half a dozen reporters here and we're nearly outnumbered by PR folks. As one of them remarked, the press turnout for an event like this just isn't what it used to be...

  • Pfizer Turns to Emerging Markets for Growth Wednesday, 5 Mar 2008 | 8:36 AM ET

    Pfizer, which is struggling to remain competitive amid generic competition for many of its products, Wednesday said it hopes to expand its sales in Asia and other emerging markets.

  • Baxter, Biogen Idec & Elan Subjects of Broken Embargoes Wednesday, 5 Mar 2008 | 8:15 AM ET

    Embargoes imposed by scientific groups and medical journals will once again be put to the test over the next couple of months.

  • Pfizer Not Getting The Love Before Analyst Meeting Tuesday, 4 Mar 2008 | 3:38 PM ET

    The day before Pfizer's analyst meeting tomorrow investors are not showing much love for the beaten-down Dow component. PFE's trading in the early going today at its lowest level since December 2005.

  • Glaxo Wins FDA Priority Review for Blood Drug Monday, 3 Mar 2008 | 11:04 AM ET

    GlaxoSmithKline's experimental platelet-boosting drug Promacta has been granted priority review by U.S. health regulators, boosting prospects for its early launch, Europe's biggest drugmaker said on Monday.

  • Drug Money Still A "Healthy Flow" To Democrats Monday, 3 Mar 2008 | 9:29 AM ET

    On the eve of the make-or-break Texas-Ohio primaries for Sen. Hillary Clinton, she remains in first place in at least one "poll." The Center for Responsive Politics has updated its list of top pharmaceuticals/health products-industry money recipients based on the most recent campaign finance reports and the former First Lady edges out Sen. Barack Obama...

  • Glaxo's Tykerb Goes Head-to-Head with Herceptin Friday, 29 Feb 2008 | 5:10 AM ET

    GlaxoSmithKline's new breast cancer drug Tykerb is to go head-to-head with Genentech's blockbuster Herceptin to see whether one is better or if patients should get both.

  • Lightning Round: Medco, Amgen, Yum! and More Thursday, 28 Feb 2008 | 8:12 PM ET

    Cramer makes the call on viewers' favorite stocks.

  • Bayer Misses Forecasts; CEO Upbeat on 2008 Thursday, 28 Feb 2008 | 1:12 PM ET

    German drugs and chemicals group Bayer missed fourth-quarter earnings expectations Thursday, sending shares 4.7 percent lower on the DAX, but CEO Werner Wenning told CNBC he remains optimistic about the company’s outlook for this year.

  • Lechleiter Likes Lilly--A Lot Thursday, 28 Feb 2008 | 9:50 AM ET

    When Schering-Plough Chairman and CEO Fred Hassan recently decided to buy another $2 million worth of SGP shares in the wake of the Vytorin study takedown, the company put out a press release.

  • Major European Companies Report Mixed Earnings Thursday, 28 Feb 2008 | 6:53 AM ET

    European earnings failed to drive broader European markets higher, as disappointing numbers from bigger names and cautious guidance mostly pushed shares in reporting companies lower.

  • Bayer Profit Misses Forecasts; Upbeat on 2008 Thursday, 28 Feb 2008 | 4:09 AM ET

    Bayer's quarterly profits missed market expectations, but the German drugs and chemicals group was upbeat about 2008 and said its healthcare and agrochemicals units would drive earnings.

  • Onyx Hires New CEO--But Here's What You Won't Find In PR Wednesday, 27 Feb 2008 | 3:28 PM ET

    Recently I've blogged and raised the question in an interview about whether Onyx Pharmaceuticals might be having a tough time finding a new leader. Well, nearly six months since longtime Chairman and CEO Hollings Renton announced his plans to retire this year, the biotech company has filled the spot.

  • Prana Biotechnology: Why I Wanted To Do Their Story Tuesday, 26 Feb 2008 | 1:13 PM ET

    I often get pitched by PR people who want me to do a story on their micro-cap biotech company. And I almost always turn them down. I know that most of the sector toils in the eight and nine digit market value space and that there's a bit of a Catch-22 at work.

  • Pfizer's CEO Kindler Being Kind To Hillary--Again Monday, 25 Feb 2008 | 1:37 PM ET

    According to The Center for Responsive Politics' web site Pfizer Chairman and CEO Jeff Kindler has opened his wallet again for Sen. Hillary Clinton. You can see his latest "give" here. Twice now within the past year Kindler has given the maximum amount ($2,300) an individual can contribute to a candidate.

  • Roche Outlook, Stock Buoyed by Avastin Approval Monday, 25 Feb 2008 | 12:48 PM ET

    Analysts raised forecasts for Roche Holding on Monday after U.S. regulators approved its Avastin drug for treating advanced breast cancer, adding a potentially significant new revenue source.

  • Genentech: How It Got Its Groove Back Monday, 25 Feb 2008 | 10:42 AM ET

    I always prefer it when pharmaceutical/biotech execs and analysts can break out of their scientific/financial jargon and give good soundbites or quotes. So, among the flurry of research notes I've received over the weekend and this morning on the Genentech Avastin news the award goes to Rodman & Renshaw's Mike King who writes, "The biotech leader has its groove back."

  • Breast Cancer Drug Avastin Approved by FDA Friday, 22 Feb 2008 | 4:57 PM ET

    A drug made by Genentech  received federal approval on Friday to treat breast cancer, a decision that could represent a major shift in standards for assessing the effectiveness of cancer medicines.

  • Genentech's Avastin Gets "Qualified" Win From FDA Friday, 22 Feb 2008 | 4:53 PM ET

    Shortly before the closing bell trading in shares of Genentech was halted for news pending. Then, right after the bell the company issued this press release announcing the Food and Drug Administration has granted "accelerated approval" to Genentech's Avastin for use on breast cancer.